Journal
ONCOTARGET
Volume 7, Issue 12, Pages 14940-14950Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7496
Keywords
bacterial therapy; ABCB5; tumor initiating cells; drug resistance; antitumor
Categories
Funding
- Chinese National Nature Sciences Foundation [81421091, 81573338]
- Ministry of Science and Technology [2012CB967004, 2014CB744501]
- Doctoral Station Science Foundation from the Chinese Ministry of Education [20130091130003]
- Jiangsu Provincial Nature Science Foundation [BE2013630]
- Open Project Program of State Key Laboratory of Natural Medicines of China Pharmaceutical University [G140014]
- Bureau of Science and Technology of Changzhou, Jiangsu, China [CZ20130011, CE20135013, CZ20120004, CM20122003, WF201207]
Ask authors/readers for more resources
Drug resistance remains an obstacle hindering the success of chemotherapy. Cancer stem cells (CSCs) have been recently found to confer resistance to chemotherapy. Therefore functional markers of CSCs should be discovered and specific therapies targeting these cells should be developed. In our investigation, a small population of B16F10 cells which was positive for ATP-binding cassette sub-family B member 5 (ABCB5) was isolated. This population displayed characteristics similar to those of CSCs and ABCB5 was identified to confer tumor growth and drug resistance in B16F10 cell line. Although targeting ABCB5 by small short interfering RNA delivered by VNP20009 failed to inhibit tumor growth, the combined treatment of VNP-shABCB5 and chemotherapy can act synergistically to delay tumor growth and enhance survival time in a primary B16F10 mice model. Results suggest that the combined treatment of VNP-shABCB5 and chemotherapy can improve the efficacy of chemotherapeutic drugs. Therefore, this combination therapy is of potential significance for melanoma treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available